34 related articles for article (PubMed ID: 12915632)
1. Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas.
Wang C; Zhang Y
Int J Nanomedicine; 2023; 18():6037-6058. PubMed ID: 37904863
[TBL] [Abstract][Full Text] [Related]
2. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of nanoparticle-mediated double suicide gene expression driven by 'E9-hTERT promoter' switch in dedifferentiated thyroid cancer cells.
Chang A; Ling J; Ye H; Zhao H; Zhuo X
Bioengineered; 2021 Dec; 12(1):6572-6578. PubMed ID: 34506254
[TBL] [Abstract][Full Text] [Related]
4. Nanocarrier-based systems for targeted and site specific therapeutic delivery.
Majumder J; Taratula O; Minko T
Adv Drug Deliv Rev; 2019 Apr; 144():57-77. PubMed ID: 31400350
[TBL] [Abstract][Full Text] [Related]
5. Functional comparison of the human epidermal growth factor receptor and telomerase reverse transcriptase promoters in canine tumor cells.
Okamoto M; Soeda T; Asamura A; Tanaka K; Watanabe K; Ikeda T
J Vet Med Sci; 2019 Mar; 81(3):397-400. PubMed ID: 30674742
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.
Sun Q; Wang X; Cui C; Li J; Wang Y
Int J Nanomedicine; 2018; 13():3713-3728. PubMed ID: 29983564
[TBL] [Abstract][Full Text] [Related]
7. Telomerase and the endocrine system.
Pacini F; Cantara S; Capezzone M; Marchisotta S
Nat Rev Endocrinol; 2011 Mar; 7(7):420-30. PubMed ID: 21448143
[TBL] [Abstract][Full Text] [Related]
8. Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer.
Shen CX; Wen Z; Qian YH; Mu SF; Guan XF
J Exp Clin Cancer Res; 2010 Jul; 29(1):94. PubMed ID: 20626878
[TBL] [Abstract][Full Text] [Related]
9. Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.
Bilsland AE; Fletcher-Monaghan A; Keith WN
Neoplasia; 2005 Nov; 7(11):1020-9. PubMed ID: 16331888
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.
Celano M; Calvagno MG; Bulotta S; Paolino D; Arturi F; Rotiroti D; Filetti S; Fresta M; Russo D
BMC Cancer; 2004 Sep; 4():63. PubMed ID: 15363094
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
Zhang R; Straus FH; DeGroot LJ
Thyroid; 2001 Feb; 11(2):115-23. PubMed ID: 11288980
[TBL] [Abstract][Full Text] [Related]
12. Viral mediated gene therapy for the management of metastatic thyroid carcinoma.
DeGroot LJ; Zhang R
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):235-44. PubMed ID: 15379725
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-dependent gene therapy.
Wirth T; Kühnel F; Kubicka S
Curr Mol Med; 2005 Mar; 5(2):243-51. PubMed ID: 15974879
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
Takeda T; Inaba H; Yamazaki M; Kyo S; Miyamoto T; Suzuki S; Ehara T; Kakizawa T; Hara M; DeGroot LJ; Hashizume K
J Clin Endocrinol Metab; 2003 Aug; 88(8):3531-8. PubMed ID: 12915632
[TBL] [Abstract][Full Text] [Related]
15. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K
Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028
[TBL] [Abstract][Full Text] [Related]
16. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
